Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: Systematic review and meta-analyses

Carla Rognoni, Oriana Ciani, Silvia Sommariva, Antonio Facciorusso, Rosanna Tarricone, Sherrie Bhoori, Vincenzo Mazzaferro

Research output: Contribution to journalReview article

Abstract

Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC). A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment. Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63% (95% CI: 56-70%) and 27% (95% CI: 21-33%) at 1-and 3-years respectively in intermediate stage HCC, whereas OS was 37% (95% CI: 26-50%) and 13% (95% CI: 9-18%) at the same time intervals in patients with sufficient liver function (Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein thrombosis. When an intermediate and advanced case-mix was considered, OS was 58% (95% CI: 48-67%) and 17% (95% CI: 12-23%) at 1-and 3-years respectively. As for TTP, only four studies reported data: the observed progression probability was 56% (95% CI: 41-70%) and 73% (95% CI: 56-87%) at 1 and 2 years respectively. The safety analysis, focused on the risk of liver decompensation after TARE, revealed a great variability, from 0-1% to more than 36% events, influenced by the number of procedures, patient Child-Pugh stage and treatment duration. Evidence supporting the use of radioembolization in HCC is mainly based on retrospective and prospective cohort studies. Based on this evidence, until the results of the ongoing randomized trials become available, radioembolization appears to be a viable treatment option for intermediate-advanced stage HCC.

Original languageEnglish
Pages (from-to)72343-72355
Number of pages13
JournalOncotarget
Volume7
Issue number44
DOIs
Publication statusPublished - 2016

Fingerprint

Meta-Analysis
Hepatocellular Carcinoma
Survival
Safety
Investigational Therapies
Diagnosis-Related Groups
Liver
Portal Vein
Thrombosis
Cohort Studies
Research Design
Therapeutics
Prospective Studies

Keywords

  • Advanced stage
  • Hepatocellular carcinoma
  • Intermediate stage
  • Meta-analysis
  • Trans-arterial radioembolization

ASJC Scopus subject areas

  • Oncology

Cite this

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma : Systematic review and meta-analyses. / Rognoni, Carla; Ciani, Oriana; Sommariva, Silvia; Facciorusso, Antonio; Tarricone, Rosanna; Bhoori, Sherrie; Mazzaferro, Vincenzo.

In: Oncotarget, Vol. 7, No. 44, 2016, p. 72343-72355.

Research output: Contribution to journalReview article

Rognoni, Carla ; Ciani, Oriana ; Sommariva, Silvia ; Facciorusso, Antonio ; Tarricone, Rosanna ; Bhoori, Sherrie ; Mazzaferro, Vincenzo. / Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma : Systematic review and meta-analyses. In: Oncotarget. 2016 ; Vol. 7, No. 44. pp. 72343-72355.
@article{c4450a2d0de4415493cf7f11da05b003,
title = "Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: Systematic review and meta-analyses",
abstract = "Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC). A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment. Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63{\%} (95{\%} CI: 56-70{\%}) and 27{\%} (95{\%} CI: 21-33{\%}) at 1-and 3-years respectively in intermediate stage HCC, whereas OS was 37{\%} (95{\%} CI: 26-50{\%}) and 13{\%} (95{\%} CI: 9-18{\%}) at the same time intervals in patients with sufficient liver function (Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein thrombosis. When an intermediate and advanced case-mix was considered, OS was 58{\%} (95{\%} CI: 48-67{\%}) and 17{\%} (95{\%} CI: 12-23{\%}) at 1-and 3-years respectively. As for TTP, only four studies reported data: the observed progression probability was 56{\%} (95{\%} CI: 41-70{\%}) and 73{\%} (95{\%} CI: 56-87{\%}) at 1 and 2 years respectively. The safety analysis, focused on the risk of liver decompensation after TARE, revealed a great variability, from 0-1{\%} to more than 36{\%} events, influenced by the number of procedures, patient Child-Pugh stage and treatment duration. Evidence supporting the use of radioembolization in HCC is mainly based on retrospective and prospective cohort studies. Based on this evidence, until the results of the ongoing randomized trials become available, radioembolization appears to be a viable treatment option for intermediate-advanced stage HCC.",
keywords = "Advanced stage, Hepatocellular carcinoma, Intermediate stage, Meta-analysis, Trans-arterial radioembolization",
author = "Carla Rognoni and Oriana Ciani and Silvia Sommariva and Antonio Facciorusso and Rosanna Tarricone and Sherrie Bhoori and Vincenzo Mazzaferro",
year = "2016",
doi = "10.18632/oncotarget.11644",
language = "English",
volume = "7",
pages = "72343--72355",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "44",

}

TY - JOUR

T1 - Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma

T2 - Systematic review and meta-analyses

AU - Rognoni, Carla

AU - Ciani, Oriana

AU - Sommariva, Silvia

AU - Facciorusso, Antonio

AU - Tarricone, Rosanna

AU - Bhoori, Sherrie

AU - Mazzaferro, Vincenzo

PY - 2016

Y1 - 2016

N2 - Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC). A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment. Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63% (95% CI: 56-70%) and 27% (95% CI: 21-33%) at 1-and 3-years respectively in intermediate stage HCC, whereas OS was 37% (95% CI: 26-50%) and 13% (95% CI: 9-18%) at the same time intervals in patients with sufficient liver function (Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein thrombosis. When an intermediate and advanced case-mix was considered, OS was 58% (95% CI: 48-67%) and 17% (95% CI: 12-23%) at 1-and 3-years respectively. As for TTP, only four studies reported data: the observed progression probability was 56% (95% CI: 41-70%) and 73% (95% CI: 56-87%) at 1 and 2 years respectively. The safety analysis, focused on the risk of liver decompensation after TARE, revealed a great variability, from 0-1% to more than 36% events, influenced by the number of procedures, patient Child-Pugh stage and treatment duration. Evidence supporting the use of radioembolization in HCC is mainly based on retrospective and prospective cohort studies. Based on this evidence, until the results of the ongoing randomized trials become available, radioembolization appears to be a viable treatment option for intermediate-advanced stage HCC.

AB - Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC). A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment. Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63% (95% CI: 56-70%) and 27% (95% CI: 21-33%) at 1-and 3-years respectively in intermediate stage HCC, whereas OS was 37% (95% CI: 26-50%) and 13% (95% CI: 9-18%) at the same time intervals in patients with sufficient liver function (Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein thrombosis. When an intermediate and advanced case-mix was considered, OS was 58% (95% CI: 48-67%) and 17% (95% CI: 12-23%) at 1-and 3-years respectively. As for TTP, only four studies reported data: the observed progression probability was 56% (95% CI: 41-70%) and 73% (95% CI: 56-87%) at 1 and 2 years respectively. The safety analysis, focused on the risk of liver decompensation after TARE, revealed a great variability, from 0-1% to more than 36% events, influenced by the number of procedures, patient Child-Pugh stage and treatment duration. Evidence supporting the use of radioembolization in HCC is mainly based on retrospective and prospective cohort studies. Based on this evidence, until the results of the ongoing randomized trials become available, radioembolization appears to be a viable treatment option for intermediate-advanced stage HCC.

KW - Advanced stage

KW - Hepatocellular carcinoma

KW - Intermediate stage

KW - Meta-analysis

KW - Trans-arterial radioembolization

UR - http://www.scopus.com/inward/record.url?scp=84995393697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995393697&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11644

DO - 10.18632/oncotarget.11644

M3 - Review article

AN - SCOPUS:84995393697

VL - 7

SP - 72343

EP - 72355

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -